E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction
Joan Llevadot,Robert P. Giugliano,Elliott M. Antman,Robert G. Wilcox,Enrique P. Gurfinkel,Timothy D. Henry,Carolyn H. McCabe,Andrew Charlesworth,S.L Thompson,Jose C. Nicolau,U Tebbe,Zygmunt Sadowski +11 more
TL;DR: There is a marked variation in procedure use by the availability of on-site catheterization with no major differences in patient outcomes, and there is a need for additional randomized trials in the current era.
Journal ArticleDOI
Sustainable Development Goals and the Future of Cardiovascular Health: A Statement From the Global Cardiovascular Disease Taskforce
William A. Zoghbi,Tony Duncan,Elliott M. Antman,Marcia C. Barbosa,Beatriz Champagne,Deborah Chen,Habib Gamra,John Gordon Harold,Staffan Josephson,Michel Komajda,Susanne Logstrup,Bongani M. Mayosi,Jeremiah Mwangi,Johanna Ralston,Ralph L. Sacco,K.H. Sim,Sidney C. Smith,Panos E. Vardas,David R. Wood +18 more
TL;DR: The authors are on the cusp of a new era in global health policy that could transform the lives of millions worldwide, and whether cardiovascular health is part of this transformation will be largely determined within the next few months.
Journal ArticleDOI
Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes
TL;DR: Despite aggressive antithrombotic therapy, a significant proportion of patients with NSTEMI ACS have recurrent ischemia precipitating urgent revascularization or infarction within the first few days, whereas the highest risk of death occurs later, after the first week.
Journal ArticleDOI
Synthesis, grading, and presentation of evidence in guidelines: article 7 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.
Gordon H. Guyatt,Elie A. Akl,Andrew D Oxman,Kevin C. Wilson,Milo A. Puhan,Timothy J Wilt,David D. Gutterman,Mark Woodhead,Elliott M. Antman,Holger J. Schünemann +9 more
TL;DR: The GRADE approach to grading the quality of evidence and presenting evidence suggests use of evidence profiles that provide a comprehensive way to display the key evidence relevant to a clinical question.
Journal ArticleDOI
Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Timothy D. Henry,Daniel Satran,Lorri L. Knox,Cheryl L. Iacarella,David D. Laxson,Elliott M. Antman +5 more
TL;DR: In contrast to heparin, ACTs are not useful for assessment of anticoagulation with subcutaneous enoxaparin and should not be relied on in patients receiving enoxAParin who require acute PCI.